by Liver fibrosis refers to the formation of fibrous scars in the liver due to chronic liver inflammation. When liver damage occurs, fibroblasts build up in the liver and deposit scar-like tissue, called fibrosis. This overgrowth of fibrous tissue eventually leads to cirrhosis and liver failure. The most common causes of liver fibrosis include hepatitis B and C infections, alcohol abuse, non-alcoholic fatty liver disease, and autoimmune liver disorders. The increasing prevalence of liver disorders and growing awareness related to early detection and treatment of liver fibrosis are the major factors driving the demaand for liver fibrosis treatment drugs and therapies.
The global Liver Fibrosis Treatment Market is estimated to be valued at US$ 16.29 Bn in 2024 and is expected to exhibit a CAGR of 4.9% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
As per a report by the European Association for the Study of the Liver, it is estimated that around 30% to 40% of the world’s population has viral hepatitis, with approximately 170-250 million patients chronically infected only with hepatitis C. The growing liver disease burden has accelerated research and development activities for novel treatment drugs and therapies targeted towards slowing and reversing liver fibrosis. Many pharmaceutical companies are conducting clinical trials to evaluate drug candidates for liver fibrosis and cirrhosis treatment. This has expanded treatment options and fueled competition in the market.
Segment Analysis
The global liver fibrosis treatment market is segmented based on treatment type, drug type, sales channel, and end users. Among treatment types, anti-fibrotic agents is the dominating sub-segment currently accounting for over 50% of the market share. This is because anti-fibrotic agents directly act on underlying fibrotic processes and helps in reversing the condition.
Key Takeaways
The global liver fibrosis treatment market is expected to witness high growth over the forecast period. The global Liver Fibrosis Treatment Market is estimated to be valued at US$ 16.29 Bn in 2024 and is expected to exhibit a CAGR of 4.9% over the forecast period 2023 to 2030.
Regional analysis related content comprises
The Asia Pacific region is expected witness fastest growth in the global liver fibrosis treatment market during the forecast period. Rapid economic development, rising healthcare expenditure, growing medical tourism industry and increasing prevalence of chronic liver diseases especially viral hepatitis are major factors driving the market growth in Asia Pacific region. China and India are anticipated to be the fastest growing markets in the region owing to availability of low cost treatment options and growing patient population.
Key players related content comprises
Key players operating in the liver fibrosis treatment market are Abbott Laboratories, Baxter International Inc., Fresenius Kabi AG, NESTLÉ S.A., DANONE S.A., B.Braun Melsungen AG, Mead Johnson & Company, LLC, Perrigo Company PLC, Koru Nutrition Inc., and Koninklijke DSM N.V. Abbott Laboratories and Baxter International Inc. currently holds majority share of the global liver fibrosis treatment market.
Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
